Globalspace Technologies converts Rs 12.64 cr loan into equity, gains 99.83% stake in Miljon Mediapp

What Globalspace Technologies announced

On 18 June 2026, the Board of Directors of Globalspace Technologies Limited approved the conversion of a loan amounting to Rs 12.64 crore into equity shares of its subsidiary, Miljon Mediapp Private Limited. The conversion will increase Globalspace’s shareholding in Miljon to 99.83%, effectively making it a near‑total owner. The transaction is classified as a non‑related‑party deal and does not require any governmental or regulatory clearances. The board set a target to complete the conversion on or before 31 July 2026.

"The Board has approved the acquisition of additional shareholding in Miljon Mediapp Private Limited pursuant to conversion of loan granted by the Company into equity shareholding," the filing states.

Details of the loan‑to‑equity conversion

• Loan amount: Rs 12.64 crore (approximately Rs 12,64,00,000).
• Consideration: The loan will be extinguished in exchange for newly issued equity shares of Miljon Mediapp. No cash outflow is involved beyond the existing loan balance.
• Shareholding post‑conversion: 99.83% of Miljon’s equity will be held by Globalspace Technologies. The remaining 0.17% will stay with existing minority shareholders, if any.
• Timing: The conversion is expected to be finalised by 31 July 2026, giving the company roughly six weeks from the board approval to complete all procedural steps.
• Regulatory framework: The transaction is disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and complies with the SEBI master circular dated 30 January 2026. No additional approvals from the Ministry of Corporate Affairs or other bodies are required.

About Miljon Mediapp Private Limited

Miljon Mediapp operates in the Pharma Tech sector. It is a digital engagement platform that helps pharmaceutical companies interact with healthcare professionals, patients, distributors, and field sales teams through a single integrated ecosystem. Key capabilities include:

• Patient support programmes and medication‑adherence initiatives.
• Digital detailing, product education, and prescription generation.
• Real‑time analytics, personalised engagement, and compliant digital workflows.

Financial snapshot (as of 31 March 2026)

• Net‑worth: Rs 31,97,000 (≈ Rs 3.2 million).
• Turnover: Nil for FY 2024‑25 and FY 2025‑26.
• Incorporation: Converted into a Limited Liability Partnership on 29 March 2025.
• Geography: Operates primarily in India; no overseas presence is disclosed.

The platform’s focus on digital transformation for pharma sales and marketing aligns with Globalspace’s broader strategy to diversify into high‑growth technology‑enabled services.

Key facts at a glance

Why this matters for investors

• Equity dilution vs ownership gain: The conversion does not involve issuing new shares to external investors; instead, an existing intra‑group loan is swapped for equity, increasing the parent’s control without diluting external shareholders.
• Balance‑sheet impact: Extinguishing a Rs 12.64 crore loan improves Globalspace’s leverage ratios, as the liability is removed from the books and replaced by an equity investment in a subsidiary.
• Strategic fit: Acquiring near‑total ownership of a pharma‑tech platform gives Globalspace exposure to a high‑growth digital health segment, potentially complementing its existing technology portfolio.
• Regulatory simplicity: The absence of related‑party concerns and the lack of required approvals streamline the transaction, reducing execution risk and associated costs.
• Financial visibility: Miljon’s current zero turnover means that any future revenue contribution will be reflected only after the platform commercialises its services, a factor investors should monitor.

Conclusion

Globalspace Technologies’ board has approved converting a Rs 12.64 crore loan into equity, raising its stake in Miljon Mediapp to 99.83%. The deal is classified as a non‑related‑party transaction, requires no external approvals, and is slated for completion by 31 July 2026. While the move strengthens the parent’s balance sheet and grants near‑full control of a pharma‑tech platform, the subsidiary’s lack of historic revenue means that material financial benefits will depend on future commercial execution.